What are Yongsheng-KY's main growth strategies?

Yongsheng-KY's main growth strategies are the 'cell triple arrows': cell new drugs, cell supply, and cell services. These are important growth drivers for the company and have already entered the harvest period.

What is the current status of Yongsheng-KY's umbilical cord blood new drug 'REGENECYTE'?

REGENECYTE has obtained FDA approval and is used for treating various hematopoietic and immune system diseases. Specifically, its long COVID treatment drug successfully unblinded Phase 2 clinical trials at the end of 2024, received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, and obtained fee approval for the 'Expanded Access Program (EAP)' in January this year. It is currently in Phase 3 clinical trials, and partnership discussions are ongoing.

AI News NQ Analysis

Yongsheng-KY's 'Cell Triple Arrows' as Growth Drivers, Plans to List in Late April

NQ Score 100/100

AI Summary (NQ-processed)

Yongsheng-KY is set to list in late April, driven by its 'cell triple arrows' strategy: cell new drugs, cell supply, and cell services. The company possesses a large-scale private and public umbilical cord blood cell bank and has obtained FDA approval for its umbilical cord blood new drug, REGENECYTE. Its long COVID treatment drug is currently in Phase 3 clinical trials with the FDA, and partnership discussions are underway. Private umbilical cord blood storage services account for 90% of its revenue, with the US market being the primary focus. Yongsheng-KY is also actively expanding into the US and Southeast Asian markets through innovative business models like the 'public bank guarantee service' in collaboration with insurers like Shin Kong Life.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What are Yongsheng-KY's main growth strategies?: A: Yongsheng-KY's main growth strategies are the 'cell triple arrows': cell new drugs, cell supply, and cell services. These are important growth drivers for the company and have already entered the harvest period.
Q: What is the current status of Yongsheng-KY's umbilical cord blood new drug 'REGENECYTE'?: A: REGENECYTE has obtained FDA approval and is used for treating various hematopoietic and immune system diseases. Specifically, its long COVID treatment drug successfully unblinded Phase 2 clinical trials at the end of 2024, received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, and obtained fee approval for the 'Expanded Access Program (EAP)' in January this year. It is currently in Phase 3 clinical trials, and partnership discussions are ongoing.